Clinical Trial Update: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

This update outlines a Phase 1 study of genetically modified T-cell infusions following peripheral blood stem cell transplant for patients with recurrent or hig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Genetically Modified T-cell Infusion (CAR-T cell therapy)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING